News

Cortex is a leader in developing drugs for respiratory disorders, particularly sleep apnea (both obstructive and central) and drug-induced respiratory depression. Premature infants exhibit frequent apneic events and

Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well tolerated, and even at the lowest dose level

The submission follows Merrimack’s recent filing of a new drug application (NDA) for this indication with the United States Food and Drug Administration (FDA). "Our coordinated U.S. and

Additionally, the CFDA has approved Xarelto for the treatment of deep vein thrombosis (DVT) and for the reduction of the risk of recurrent DVT and pulmonary embolism (PE)

As part of the deal, Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need. Under the clinical development program, Bayer will evaluate the

AQX-1125 is a small molecule activator of SHIP1 suitable for oral, once daily dosing and it has been evaluated in multiple preclinical studies and clinical trials. The randomized,

The joint collaboration will focus on biomarkers that may facilitate therapeutic approaches targeting alpha-synuclein, a protein potentially involved in the onset and progression of PD. MJFF CEO Todd

Sovaldi is indicated to treat chronic hepatitis C infection as a component of a combination antiviral treatment regimen. In February 2015, Gilead appointed Mylan as its exclusive distributor

BL-8040 is a clinical-stage drug candidate designed to treat AML, as well as other hematological indications. The company intends to report top-line results from the trial in the